Product Information:

ARMAPE

PAI-1 is a serine protease inhibitor (SERPIN). PAI-1 binds to and irreversibly inhibits uPA, tPA and furin; it also interacts with vitronectin, α1-acid glycoprotein, CRT, TLR4, proteasome α-3 subunit, uPAR, LRP1, Integrin αvβ3 and thrombin. PAI-1 regulates fibrinolysis, extracellular matrix turnover, cell migration, angiogenesis, inflammatory response and tissue remodeling; it mediates epithelial-mesenchymal transition (EMT)/endothelial-mesenchymal transition (EndMT), apoptosis and thrombus stabilization. PAI-1 can be used in research related to sepsis, acute lung injury, cardiovascular diseases, tissue fibrosis, diabetic nephropathy, obstructive nephropathy and non-insulin-dependent diabetes mellitus .


Cat. No.: EX-A17250	Purity: >98%

	Chemical structure of ARMAPE

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	139446-70-1
Purity	>98%
Formula	C27H47N9O9S
Mol Weight	673.782
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Park YJ, et al. PAI-1 inhibits neutrophil efferocytosis. Proceedings of the National Academy of Sciences of the United States of America. 2008 Aug 19;105(33):11784-9. [2]. Sillen M, et al. Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. Frontiers in cardiovascular medicine. 2020;7:622473. [3]. Ghosh AK, et al. PAI-1 in tissue fibrosis. Journal of cellular physiology. 2012 Feb;227(2):493-507. [4]. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol. 2008 Feb;19(2):329-38. [5]. Ehrlich HJ, et al. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry. 1991 Jan 29;30(4):1021-8. [6]. Oda T, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney international. 2001 Aug;60(2):587-96. [7]. Matsuo S, et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int. 2005 Jun;67(6):2221-38. [8]. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005 Aug;3(8):1879-83. [9]. Tang Z, et al. Surface immobilization of a protease through an inhibitor-derived affinity ligand: a bioactive surface with defensive properties against an inhibitor. Chemical communications (Cambridge, England). 2015 Sep 28;51(75):14263-6. [10]. Nordt TK, et al. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995 Feb 01;91(3):764-70.
CoA	CoA of ARMAPE

Smiles:	C([C@@H](NC([C@@H](NC([C@H](CCCNC(=N)N)NC([C@H](C)N)=O)=O)CCSC)=O)C)(=O)N1[C@H](C(N[C@@H](CCC(O)=O)C(O)=O)=O)CCC1


		Search